Reaction

Immune-Mediated Hepatitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,938 reports · 46 co-occurring drugs

As of the last recalculation, Immune-Mediated Hepatitis appears in 1,938 FAERS reports alongside 46 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 176.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ipilimumab	521	176.9	179.1
Nivolumab	731	129.8	130.8
Pembrolizumab	693	109.6	110.3
Durvalumab	106	59.1	59.4
Atezolizumab	188	57.5	57.7
Pemetrexed	94	49.4	49.6
Pemetrexed Disodium	122	36.6	36.7
Carboplatin	346	35.4	35.5
Lenvatinib	96	33.0	33.1
Paclitaxel	249	30.8	30.9
Paclitaxel (Aibumin-Bound)	207	30.2	30.2
Encorafenib	18	19.7	19.7
Bevacizumab	150	14.0	14.0
Axitinib	24	13.4	13.4
Gemcitabine Hydrochloride	62	12.9	12.9
Cabozantinib	54	12.4	12.4
Entecavir	13	12.0	12.0
Febuxostat Tablets 40 Mg	11	11.7	11.7
Febuxostat Tablets 80 Mg	11	11.7	11.7
Gemcitabine	39	10.8	10.8
Ampicillin	8	10.4	10.4
Ampicillin Sodium	8	10.4	10.4
Trametinib	22	9.9	9.9
Dabrafenib	19	9.8	9.8
Ursosiol	17	9.5	9.5
Atovaquone	7	9.4	9.4
Dexamethasone Sodium Phosphate	8	8.5	8.5
Ursodiol	17	8.4	8.5
Oxaliplatin	53	7.9	7.9
Regorafenib	8	7.4	7.4
Granisetron Hydrochloride	7	7.2	7.2
Granisetron	7	7.2	7.2
Vemurafenib	8	7.2	7.2
Febuxostat	11	7.1	7.1
Dapagliflozin	20	6.9	6.9
Metoclopramide	33	6.6	6.6
Aprepitant	10	5.8	5.8
Fosaprepitant Dimeglumine	7	5.5	5.5
Cisplatin	38	5.3	5.3
Etoposide	32	4.7	4.7
Fluorouracil Cream, 0.5%	32	4.6	4.6
Brentuximab Vedotin	4	4.2	4.2
Abiraterone	5	4.0	4.0
Alpelisib	3	3.7	3.7
Olaparib	7	3.6	3.6
Pazopanib Hydrochloride	8	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.